TZIELD® (teplizumab-mzwv) is the first and only FDA approved treatment indicated to delay the onset of Stage 3 Type 1 Diabetes for people 8 years and older who have Stage 2 Type 1 …

Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in …

Tzield is a CD3-directed antibody that binds to and may deactivate pancreatic beta cell auto-reactive T lymphocytes. Tzield is administered by intravenous infusion...

2022年11月22日 · 近日，该公司宣布，美国食品和药物 管理 局（FDA）已批准 Tzield（teplizumab-mzwv）注射液：该药是一种静脉注射的抗CD3单抗，作为第一种也是唯一 …

TZIELD is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D (1).

2023年3月4日 · Teplizumab 是由 Provention Bio 公司开发的靶向T细胞表面 CD3分子 的单克隆抗体，用于延迟 1型糖尿病 高危患者的发病。 该药2022年11月获美国FDA批准上市（TZIELD® …

2024年4月9日 · 2022年11月17日，Provention Bio生物制药公司宣布美国食品药品监督管理局（FDA）批准了Tzield（teplizumab-mzwv）的生物制品许可申请（BLA），用于延缓8岁及以 …

TZIELD is a CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. …

2023年12月8日 · TZIELD® (teplizumab-mzwv) injection, for intravenous ... TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and …

2024年10月10日 · TZIELD is a drug that is used to delay the onset of type 1 diabetes in children and adults who are at high risk for type 1 diabetes. How is this drug used? TZIELD is an …